FACSIMILE TRANSMITTAL

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road
Suite 200
Menlo Park, California 94025
Telephone (650) 327-3400
Facsimile (650) 327-3231

Date:	July 10, 2001
To:	**Examiner Grun** U.S. Patent & Trademark Office Washington, D.C.
Facsimile No.:	**(703) 308-4242**
From:	Paula A. Borden, Patent Agent (650) 833-7710
Re:	U.S. Patent Application No. 09/269,874 corresponding to International Application No. PCT/EP97/05441 Filing Date: August 2, 1999 Inventor(s): Bujard Title: RECOMBINANTS PROCESS FOR PREPARING A COMPLETE MALARIA ANTIGEN, GP190/MSP1 Attorney Docket No.: GRUE-003
Message:	**Copy of Our Response to Office Action dated December 19, 2000 -- filed on January 19, 2001**

Total number of pages, including this cover sheet: **14**

****

#1918
7/12/01

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.			
Typed or Printed Name	Mathew Otts		
Signature		Date	January 19, 2001

RESPONSE TO RESTRICTION REQUIREMENT AND NOTICE TO COMPLY AND PRELIMINARY AMENDMENT	Attorney Docket	GRUE-003
	First Named Inventor	Bujard
	Application Number	09/269,874
	Filing Date	August 2, 1999
	Group Art Unit	1641
Address to: Assistant Commissioner for Patents Washington, D.C. 20231	Examiner Name	J. Grun
	Title	Recombinants Process for Preparing a Complete Malaria Antigen, GP190/MSP1

Sir:

This is in response to the Office Action dated December 19, 2000, which set a one-month period for response, making this response due on or before January 19, 2001. Accordingly, this response is timely filed..

Restriction Requirement

In the Office Action dated December 19, 2000, the Examiner required election of one of the following groups of claims:

Group I, including claims 42-49 and 53-57, directed to a method of producing a protein;

Group II, including claims 50-52, directed to a method of producing a nucleotide sequence;

Group III, including claims 58-69, 70-72, 73-78 and 81, directed to a group of related products (encoding nucleic acids, vectors comprising the nucleic acids, and host cells comprising the nucleic acids) sharing a technical feature (i.e., nucleic acids);

Group IV, including claim 80, directed to a given product (vaccine composition);

Group V, including claim 79, directed to a therapeutic method using a protein product; and

Group VI, including claim 82, directed to a method of stabilizing a gene sequence.